VERVE-102 for adults with or at high risk for heart disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2 interventional trial compares VERVE-102 to placebo in adults who have established atherosclerotic cardiovascular disease or are at high risk for developing it. Participants will receive VERVE-102 or placebo to see how it changes LDL cholesterol levels. The study excludes people with homozygous familial hypercholesterolemia, chronic liver disease, or current/prior use of PCSK9 inhibitors within the specified timeframe. Lead sponsor is Verve Therapeutics, with Epic Medical Research in DeSoto, Texas as the site. Outcomes focus on LDL-C reduction as a key efficacy signal and safety monitoring will be conducted.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Established atherosclerotic cardiovascular disease (ASCVD) and/or at a high risk of ASCVD

Exclusion Criteria:

* History of confirmed or suspected homozygous familial hypercholesterolemia (HoFH)
* Chronic liver disease
* Current treatment with PCSK9 inhibitor or prior treatment within specified timeframe

Where it's running

• Epic Medical Research
  DeSoto, Texas, United States Recruiting

Study contacts

• Study coordinator: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
• Email: LillyTrials@Lilly.com
• Phone: 317-615-4559

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Clazakizumab for adults with high hsCRP at risk for a heart event

  This study tests whether clazakizumab can lower inflammation and reduce cardiovascular risk in adults with high hsCRP and existing risk factors.

  Recruiting at 32 sites Phase 2 Eli Lilly and Company · Huntsville, Alabama and 45 other locations · NCT07783802

• Moderate-Intensity Statin + Ezetimibe vs High-Intensity Statin in CKD with ASCVD

  In adults with chronic kidney disease and established cardiovascular disease, this study tests whether a moderate-intensity statin plus ezetimibe can match the benefits of a high-intensity statin alone over three years.

  Recruiting Yonsei University · Seoul · NCT07524101

• Cardiovascular risk assessment for patients with lipid disorders in emergency care

  This study is testing a new way to help emergency room patients with high cholesterol lower their heart disease risk by providing better care compared to the usual treatment.

  Recruiting Phase 2 Wake Forest University Health Sciences · Winston-Salem, North Carolina · NCT06488105

• Guideline-based lipid lowering approach in Asia-Pacific patients

  This study tests if a special cholesterol management plan helps people in the hospital for a heart attack feel better compared to standard care.

  Recruiting at 11 sites Monash University · Wollongong, New South Wales and 21 other locations · NCT05325034

• Understanding the causes and progression of lipid disorders

  This study is trying to understand what causes lipid disorders, like high cholesterol, by looking at people's blood fat levels and genetics to improve how we diagnose and treat these conditions.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT00353782

• Cardio-Metabolic Clinic care for adults with type 2 diabetes and cardiovascular disease

  This trial tests whether a specialized Cardio-Metabolic Clinic can improve heart function and overall health for adults with type 2 diabetes and cardiovascular disease compared with usual care.

  Recruiting Odense University Hospital · Svendborg · NCT07878325

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.